SCHEMBL3537291

SCHEMBL3537291

CC1CCN(c2cc(Cl)c([N+](=O)[O-])cc2F)CC1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.74
MAPT P10636 9/20 0.72
MAPK1 P28482 4/20 0.72
LMNA P02545 3/20 0.67
GAA P10253 1/20 0.67
HTT P42858 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
GPR174 Q9BXC1 6/20 0.63
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
PKM P14618 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CTPS1 P17812 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3540055 0.89 MAPT (0.68) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL25198104 0.85 ALDH1A1 (1.00) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL7545283 0.83 MAPK1 (0.69) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL14217252 0.82 ALDH1A1 (0.70) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL3542275 0.82 MAPT (0.76) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL7546017 0.81 MAPT (0.71) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL7544057 0.81 MAPT (0.69) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL22621283 0.78 GPR174 (1.00) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL25188742 0.77 ALDH1A1 (0.71) ALDH1A1MAPTMAPK1LMNAGAA
SCHEMBL22621221 0.75 GPR174 (1.00) ALDH1A1MAPTMAPK1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
CN-101084208-A Aromatic amides as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-12-05 CN disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885MAPT 159/4885MAPK1 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.